PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation

We have recently demonstrated that macrophage-specific loss of Protein tyrosine phosphatase non-receptor type 2 (PTPN2) promotes inflammasome activation, resulting in protection from colorectal cancer. Here we place these findings in context with the role of inflammasomes in colorectal carcinoma, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Spalinger, Marianne R., Scharl, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149699/
https://www.ncbi.nlm.nih.gov/pubmed/30250914
http://dx.doi.org/10.1080/23723556.2018.1465013
_version_ 1783356853612183552
author Spalinger, Marianne R.
Scharl, Michael
author_facet Spalinger, Marianne R.
Scharl, Michael
author_sort Spalinger, Marianne R.
collection PubMed
description We have recently demonstrated that macrophage-specific loss of Protein tyrosine phosphatase non-receptor type 2 (PTPN2) promotes inflammasome activation, resulting in protection from colorectal cancer. Here we place these findings in context with the role of inflammasomes in colorectal carcinoma, and with a recent study indicating that PTPN2-silencing promotes anti-cancer immunotherapy.
format Online
Article
Text
id pubmed-6149699
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61496992019-06-06 PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation Spalinger, Marianne R. Scharl, Michael Mol Cell Oncol Author's Views We have recently demonstrated that macrophage-specific loss of Protein tyrosine phosphatase non-receptor type 2 (PTPN2) promotes inflammasome activation, resulting in protection from colorectal cancer. Here we place these findings in context with the role of inflammasomes in colorectal carcinoma, and with a recent study indicating that PTPN2-silencing promotes anti-cancer immunotherapy. Taylor & Francis 2018-06-06 /pmc/articles/PMC6149699/ /pubmed/30250914 http://dx.doi.org/10.1080/23723556.2018.1465013 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Spalinger, Marianne R.
Scharl, Michael
PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
title PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
title_full PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
title_fullStr PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
title_full_unstemmed PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
title_short PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
title_sort ptpn2 as a promoter of colon carcinoma via reduction of inflammasome activation
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149699/
https://www.ncbi.nlm.nih.gov/pubmed/30250914
http://dx.doi.org/10.1080/23723556.2018.1465013
work_keys_str_mv AT spalingermarianner ptpn2asapromoterofcoloncarcinomaviareductionofinflammasomeactivation
AT scharlmichael ptpn2asapromoterofcoloncarcinomaviareductionofinflammasomeactivation

Ejemplares similares